GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development
- 1 September 2007
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 25, B61-B71
- https://doi.org/10.1016/j.vaccine.2007.06.038
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Persistence of Tumor Infiltrating Lymphocytes in Adoptive Immunotherapy Correlates With Telomere LengthJournal of Immunotherapy, 2007
- Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II studyBritish Journal of Cancer, 2006
- Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic MelanomaJournal of Immunotherapy, 2006
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006
- Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibodyBlood, 2005
- Tissue Microarray Evaluation of Melanoma Antigen E (MAGE) Tumor-Associated Antigen ExpressionAnnals of Surgery, 2002
- A Phase I Trial of an HLA-A1 Restricted MAGE-3 Epitope Peptide with Incomplete Freundʼs Adjuvant in Patients with Resected High-Risk MelanomaJournal of Immunotherapy, 1999
- Expression of MAGE genes in primary and metastatic cutaneous melanomaInternational Journal of Cancer, 1995
- Expression of mage genes in transitional‐cell carcinomas of the urinary bladderInternational Journal of Cancer, 1995
- Structure, chromosomal localization, and expression of 12 genes of the MAGE familyImmunogenetics, 1994